Cardiac Science Powerheart, CardioVive, CardioLife; GE Responder and Responder Pro; and Nihon-Kohden Automated External Defibrillator

Cardiac Science Powerheart, CardioVive, CardioLife; GE Responder and Responder Pro; and Nihon-Kohden Automated External Defibrillators (AEDs): Class I Recall - Defective Component

Affected Models include:

• Powerheart 9300A, 9300E, 9300P, 9390A, and 9390E
• CardioVive 92532, 92533
• CardioLife 9200G and 9231
• GE Responder and Responder Pro
• Nihon-Kohden AEDs 

AUDIENCE: Emergency Medicine, Cardiology, Risk Manager

ISSUE: FDA notified healthcare professionals and medical care organizations of the Class 1 recall of the listed AEDs which contain a component that may fail unexpectedly due to a defect. If the component were to fail during a rescue attempt, the AED may not deliver defibrillation therapy, causing serious adverse health consequences, including death. The unit’s self test may not detect the failure or impending failure of the component.

BACKGROUND: These products are used for emergency treatment of victims showing symptoms of sudden cardiac arrest who are unresponsive and not breathing. These AEDs were manufactured and distributed from July 1, 2011 through December 30, 2011.

RECOMMENDATION: Affected customers are advised to contact the firm to arrange for delivery of shipping materials for an immediate return of their AEDs for repair. The affected devices will receive a hardware correction, and the same serial number device will be returned to the customer in most cases.

Read the MedWatch safety alert, including links to the Recal Notice and Letter, at:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm294538.htm

Related articles

• FDA Issues Defibrillator Recall
• MedWatch, Part of the FDA, Needs You
• DePuy Knee Sleeve Failure Allegation Claims Now Being Investigated by Resource4thePeople Attorneys
• Fresenius Kabi AG Voluntarily Recalls One Lot of Magnesium Sulfate Injection
• Automated External Defibrillator Market to Reach $930 Million by 2017 - New Report by MarketsandMarkets
• More Oversight Of AEDs Proposed By FDA
• Got a complaint about a medical device or drug? There's an app for that
• Catholic schools in London and Middlesex getting defibrillators
• An Automated External Defibrillator (AED) and Pocket Mask
• Nihon Kohden America Previews New Robust, Lightweight Transport Monitor

Magnesium Sulfate: against prolongued use in pre-term labor

Magnesium Sulfate: Drug Safety Communication - Recommendation Against Prolonged Use in Pre-term Labor

AUDIENCE: OB/GYN, Nursing, Risk Manager
ISSUE: FDA is advising health care professionals against using magnesium sulfate injection for more than 5-7 days to stop pre-term labor in pregnant women. Administration of magnesium sulfate injection to pregnant women longer than 5-7 days may lead to low calcium levels and bone problems in the developing baby or fetus, including thin bones (osteopenia), and fractures. The shortest duration of treatment that can result in harm to the baby is not known. See the Data Summary in the Drug Safety Communication for additional information.
BACKGROUND: This use of the drug is off-label, and is not an FDA-approved use of the drug. Magnesium sulfate is approved to prevent seizures in preeclampsia, a condition in which the pregnant woman develops high blood pressure and protein in the urine, and for control of seizures in eclampsia. Both preeclampsia and eclampsia are life-threatening complications that can occur during pregnancy. Preeclampsia can lead to eclampsia, seizures, stroke, multiple organ failure, and death of the woman and/or baby.
RECOMMENDATIONS: In light of this new safety information about low calcium levels and bone problems in the developing baby, the following information is being added to the drug label for Magnesium Sulfate Injection, USP 50%:

• A new Warning stating that continuous administration of magnesium sulfate injection beyond 5-7 days in pregnancy for the treatment of pre-term labor can cause low calcium levels and bone changes in the baby.
• A new Teratogenic Effects section conveying the potential harm to developing babies by changing the Pregnancy Category to D from A. Pregnancy Category D means there is positive evidence of human fetal risk, but the potential benefits from using the drug in pregnant women may be acceptable in certain situations despite its risks.
• A new Labor and Delivery section emphasizing that continuous administration of magnesium sulfate injection to treat pre-term labor is not approved and that the safety and efficacy of use for this indication are not established. When used in pregnant women for conditions other than its approved indication, magnesium sulfate injection should be administered only by trained obstetrical personnel in a hospital setting with appropriate obstetrical care facilities.

Pregnant women should discuss with their health care professional the possibility of going into labor before term and the risks and benefits of any treatments that may be used.
Read the MedWatch safety alert, including a link to the Drug Safety Communication, at:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm354603.htm

Related articles

• Fresenius Kabi AG Voluntarily Recalls One Lot of Magnesium Sulfate Injection
• Color Me Pregnant - Is hair dye safe while expecting?
• Opportunity To Study Pregnant Women In Large National Study Must Not Be Missed, Experts Say
• Fresenius Kabi USA Initiates Voluntary Recall of Single Lot of Magnesium Sulfate
• Fresenius Kabi USA Initiates Voluntary Recall of Single Lot of Magnesium Sulfate
• Preeclampsia: It's Scarier than it Sounds
• Magnesium Sulfate Production Equipment
• Taking Epsom Salt Bath
• Union County Walkers Make Strides To Raise Awareness Of Preeclampsia
• Bathe The Inches Away

Anticoagulant Citrate Phosphate Dextrose Solution

Anticoagulant Citrate Phosphate Dextrose Solution, USP (CPD) BLOOD-PACK Unit By Fenwal: Recall - Labeling Issue Identified

Read the MedWatch Safety Alert, including links to the Recall at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm350275.htm
AUDIENCE: Risk Manager, Health Professional, Pharmacy
ISSUE: Fenwal has initiated a voluntary Urgent Product Recall of one lot (FM13A15027) of product code 4R1584, Anticoagulant Citrate Phosphate Dextrose Solution, USP (CPD) BLOOD-PACK unit.  Fenwal identified a labeling issue with this batch of Product Code 4R1584 in which the platelet container is incorrectly labeled as “AS-1 Red Blood Cell Adenine-Saline added”. 
BACKGROUND: To date, there is only one reported occurrence of this incident and no safety concerns have been raised.
RECOMMENDATION: Fenwal is recommending that cus

Related articles

• Hematology For Undergraduate Part 2
• Hospira, Inc. Recalls Piperacillin and Tazobactam for Injection Due to Precipitation/Crystallization
• Stryker Orthopaedics - ShapeMatch Cutting Guide: Class 1 Recall
• Three ways firms can improve public perception
• First Drive: 2008 Mini Cooper Clubman S
• Got a complaint about a medical device or drug? There's an app for that
• Medprep Consulting Inc. announces nationwide recall of Magnesium Sulfate 2 grams in Dextrose 5%, citing mold contamination @FDArecalls
• Nora Apothecary & Alternative Therapies Announces a Voluntary Multi-State Recall of All Sterile Compounded Products Due to a Lack of Sterility Assurance
• Infections in Older Adults Linked to Dangerous Blood Clots in Lungs and Veins
• Voluntary Nationwide Recall of 15 Lots of Piperacillin and Tazobactam for Injection, USP 40.5 Grams Due to Possibility of Precipitation / Crystallization in IV Bag or IV Line Upon Reconstitution

Med Prep Consulting Inc. Compounded Products: Recall - Potential Mold Contamination

AUDIENCE: Risk Manager, Pharmacy, Family Practice
ISSUE: Med Prep Consulting, Inc. notified the public that it is recalling all lots of all products compounded at its facility, due to lack of sterility assurance. The level of recall is to the user: regional hospital pharmacies and related departments, and physician’s office practices. The recall resulted from the pharmacy being notified by a Connecticut hospital that it observed visible particulate contaminants in 50 ml bags of MAGNESIUM SULFATE 2GM IN DEXTROSE 5% IN WATER, 50ML FOR INJECTION intravenous solution, confirmed to be mold. These were unique and distinct lots compounded and dispensed by the pharmacy to the Connecticut hospital. At this time a total of five (5) contaminated bags were discovered. See the Med Prep Press Release for a list of affected products.
Administration of an intravenous product found to be contaminated with mold could result in a fatal infection in a broad array of patients.
BACKGROUND: The affected products are used for a wide range of therapeutic uses for hospitalized inpatients and outpatients, and, patients directly treated by a health care professional at a physician’s office practice facility or clinic. None of these products are dispensed directly to patients from retail pharmacies or to home care patients for either self-administration or nursing administration.
All products are packaged in plastic infusion bags, plastic infusion devices, plastic syringes and glass vials. Products packaged in plastic infusion bags, plastic infusion devices, plastic syringes and glass vials were distributed directly to regional hospital pharmacies located in New Jersey, Pennsylvania, Connecticut, and Delaware. Products packaged in plastic syringes only, were distributed nationwide to physician’s office practice facilities and clinics. All of these products were distributed to the described users through March 13, 2013, from Tinton Falls, New Jersey to both regional and nationwide locations.
RECOMMENDATION: All facilities that received any product compounded by Med Prep Consulting, Inc. have been notified by telephone fax, electronic mail and regular mail of the recall and have been instructed to remove and return the product to the pharmacy. Facilities with questions may contact the company at 732-493-3390, Monday through Friday, between 10:00 a.m. and 5:00 p.m. EST.
Read the MedWatch safety alert, including a link to the Press Release, at:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm344259.htm

Related articles

• FDA warns of mold in recalled specialty drugs
• Tinton Falls compounding pharmacy recalls dozens of drugs nationwide
• FDA warns of mold in recalled specialty drugs
• FDA warns of mold in recalled specialty drugs
• Medprep Consulting Inc. announces nationwide recall of Magnesium Sulfate 2 grams in Dextrose 5%, citing mold contamination @FDArecalls
• The Truth About Contaminated Breast Implants
• Visible mold forces recall of N.J. pharmacy injection drugs
• FDA warns of mold in recalled specialty drugs
• N.J. Pharmacy Med Prep Consulting Recalls Products Due To Potential Mold Contamination
• State Investigating New Jersey Based Pharmacy